secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001193125-25-005009
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon provides 2025 outlook; targets BLA submission for ANX005 in GBS in 1H 2025
--------------------------------------------------------------------------------

- ANX005 for GBS: Phase 3 showed rapid muscle strength improvement vs placebo; BLA submission targeted for 1H 2025.
- ANX007 for GA: Phase 3 ARCHER II enrollment on track for completion in 2H 2025; data expected 2H 2026.
- ANX1502 oral C1s inhibitor: clinical proof-of-concept data in CAD expected in 1Q 2025.
- Cash runway sufficient into 2H 2026 to achieve key milestones.
- Positive Phase 2 ARCHER data for ANX007 showed significant vision preservation on BCVA and LLVA endpoints.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312525005009/0001193125-25-005009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312525005009/d38866d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-005009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer